Active substance
Potassium acetate
- SFDA 1
- US FDA 4
- Health Canada 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| POTASSIUM ACETATE INJ F.T.V. 40MEQ | 40 mEq | Injection · Intravenous use | 1 Vial | SAR 11.20 | Generic · Prescription | HOSPIRA INC | Valid |
Indications — CHI Daman Drug Formulary
DIARRHEA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| POTASSIUM ACETATE | 2MEQ/ML | injectable · injection | HOSPIRA | Prescription | 20 Jul 1984 |
| POTASSIUM ACETATE | 2MEQ/ML | injectable · injection | EXELA PHARMA | Prescription | 20 Oct 2021 |
| POTASSIUM ACETATE | 2MEQ/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 27 Nov 2024 |
| POTASSIUM ACETATE | 2MEQ/ML | injectable · injection | EXELA PHARMA | Discontinued | 29 Dec 2015 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| POTASSIUM ACETATE INJECTION USP | 02362597 | 39.2 % / W/V | SOLUTION · INTRAVENOUS | JUNO PHARMA CANADA INC. |
Combinations containing Potassium acetate
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.